<description>&lt;p&gt;Dr&amp;nbsp;Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed&amp;nbsp;antibody-drug&amp;nbsp;conjugates in the management of non-small cell lung cancer.&amp;nbsp;&lt;/p&gt;&lt;p&gt;CME information and select publications &lt;a href="https://www.researchtopractice.com/5MJC2025/TROP2Lung/4" rel="noopener noreferrer" target="_blank"&gt;here&lt;/a&gt;. &lt;/p&gt;</description>

Lung Cancer Update

Dr. Neil Love

Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

NOV 10, 202521 MIN
Lung Cancer Update

Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

NOV 10, 202521 MIN

Description

Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.